Q3 2025 saw strong sales growth of 14.3%, robust digital expansion, and a 32.6% rise in private label sales. EBITDA and cash flow improved, while net income was impacted by higher interest rates. The outlook remains positive, with continued focus on digital, private label, and generics.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.